688658 Youcare Pharmaceutical Group
- 16.53
- +0.52+3.25%
Youcare Pharmaceutical Group News
We Think Youcare Pharmaceutical Group (SHSE:688658) Is Taking Some Risk With Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Yuekang Pharmaceutical (688658.SH) announced first-quarter results, net profit of 69.3054 million yuan, down 18.72% year-on-year
Yuekang Pharmaceutical (688658.SH) disclosed its report for the first quarter of 2024. The company achieved operating revenue during the reporting period...
Youcare Pharma Gets Nod for Registration of Gastric Drug
Youcare Pharmaceutical Group (SHA:688658) received a drug registration certificate from China's National Medical Products Administration for its esomeprazole sodium for injection, according to the com
Express News | Yuekang Pharmaceutical: injectable esomeprazole sodium obtained drug registration certificate
Yuekang Pharmaceutical (688658.SH): It has repurchased a total of 4.143,400 shares at a cost of 76.779,800 yuan
Gelonghui, April 2, 丨 Yuekang Pharmaceutical (688658.SH) announced that as of March 31, 2024, the company had repurchased a total of 4.143,400 shares, accounting for 0.9208% of the company's total share capital of 450,000,000 shares. The highest purchase price was 22.30 yuan/share, the lowest price was 13.46 yuan/share, and the cumulative total transaction amount was RMB 76.7798 million.
Youcare Pharmaceutical Group Co., Ltd.'s (SHSE:688658) Stock Price Dropped 9.5% Last Week; Private Companies Would Not Be Happy
Key Insights Youcare Pharmaceutical Group's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 5 investors have
Yuekang Pharmaceutical (688658.SH): Has repurchased a total of 0.8116% of shares
Gelonghui, March 4, 丨 Yuekang Pharmaceutical (688658.SH) announced that as of February 29, 2024, the company had repurchased a total of 3.652,200 shares, accounting for 0.8116% of the company's total share capital of 450,000,000 shares. The highest purchase price was 22.30 yuan/share, the lowest price was 13.46 yuan/share, and the cumulative total transaction amount was RMB 68.2663 million.
Youcare Pharmaceutical Group Co., Ltd.'s (SHSE:688658) Dismal Stock Performance Reflects Weak Fundamentals
Youcare Pharmaceutical Group (SHSE:688658) has had a rough three months with its share price down 25%. We decided to study the company's financials to determine if the downtrend will continue as the
Yuekang Pharmaceutical (688658.SH): Tongluo Brain Health Tablet's New Drug Marketing Application Accepted
Gelonghui March 1 丨 Yuekang Pharmaceutical (688658.SH) announced that the company's subsidiary Guangzhou Yuekang Biopharmaceutical Co., Ltd. received the “Notice of Acceptance” approved and issued by the State Drug Administration, and the company's application for a new drug marketing license for Tongluo Brain Tablets was accepted. The prescription for Tongluo Brain Health tablets comes from empirical formula. It is composed of ginkgo biloba extract, dilong, horny goat, chuanxiong, and yuanzhi traditional Chinese medicine. The medicines complement each other and have the effects of activating blood circulation, expectorant communication, and strengthening the brain to treat vascular dementia (brain stasis).
Express News | Yuekang Pharmaceutical: Zihuawen's new lung cough relief granule marketing application accepted
Yuekang Pharmaceutical (688658.SH) Performance Report: After deducting 132 million yuan of non-net profit in 2023, a year-on-year decrease of 50.90%
Gelonghui, Feb. 23: Yuekang Pharmaceutical (688658.SH) announced the 2023 Annual Results Report. In 2023, the company achieved total operating revenue of 4.197 billion yuan, down 7.60% from the same period last year; realized operating profit of 234 million yuan, down 34.53% from the same period last year. Net profit attributable to owners of the parent company after deducting non-recurring profit and loss was 132 million yuan, down 50.90% from the same period last year.
Yuekang Pharmaceutical (688658): BIGPHARMA's innovative traditional Chinese medicine hydroxyl A, which combines innovation and profit, ushered in increased performance
Key investment points Investment logic: As a large pharmaceutical enterprise group, the company is both profitable and innovative. 1) Ginkgo biloba extract, a high-Maori variety, has had the highest market share among cardiovascular injections for many years; 2) The echelon of various innovative products is expected within three years
Yuekang Pharmaceutical (688658.SH): The product compound ginkgo biloba is a new class 1.1 traditional Chinese medicine
Gelonghui Feb. 6 丨 Yuekang Pharmaceutical (688658.SH) said on the investor interactive platform that the company's product compound ginkgo biloba is a new class 1.1 traditional Chinese medicine. The prescription is derived from empirical formulations. It consists of ginkgo biloba extract, earthworm, horny goat, chuanxiong, and yuanzhi traditional Chinese medicine. The medicines complement each other and have the effects of activating blood circulation, expectorant circulation, and strengthening the brain to treat vascular dementia (brain stasis). Phase III clinical trials have now been completed.
Yuekang Pharmaceutical (688658.SH): A total cost of 57.376,000 yuan to buy back 0.6575% of the shares
Gelonghui, February 4, 丨 Yuekang Pharmaceutical (688658.SH) announced that as of January 31, 2024, the company had repurchased 2,958,598 shares, accounting for 0.6575% of the company's total share capital of 450,000,000 shares. The highest purchase price was 22.30 yuan/share, the lowest price was 16.23 yuan/share, and the cumulative total transaction amount was RMB 57,376,370.58.
Youcare Pharmaceutical's Antibiotic Passes Generic Drug Evaluation
Youcare Pharmaceutical Group (SHA:688658) said its Cefazolin Sodium drug, an antibiotic used for treating various bacterial infections, has passed the national consistency evaluation for generic drugs
Express News | Yuekang Pharmaceutical: injectable cefazolin sodium passed generic drug consistency evaluation
Some Confidence Is Lacking In Youcare Pharmaceutical Group Co., Ltd. (SHSE:688658) As Shares Slide 26%
Youcare Pharmaceutical Group Co., Ltd. (SHSE:688658) shareholders won't be pleased to see that the share price has had a very rough month, dropping 26% and undoing the prior period's positive performa
Yuekang Pharmaceutical (688658.SH): A total of 2,8201 thousand shares have been repurchased at a cost of 54.9811 million yuan
Gelonghui, January 3, 丨 Yuekang Pharmaceutical (688658.SH) announced that as of December 31, 2023, the company had repurchased 2,8201 thousand shares, accounting for 0.6267% of the company's total share capital of 450,000,000 shares. The highest purchase price was 22.30 yuan/share, the lowest price was 16.64 yuan/share, and the cumulative total transaction amount was RMB 54.9811 million.
Yuekang Pharmaceutical (688658.SH): The marketing application for a new injectable hydroxysafflower yellow A drug was accepted
Yuekang Pharmaceutical (688658.SH) announced that the company has received approval from the State Drug Administration (“China Drug Administration”)...
Youcare Pharmaceutical Group Co., Ltd.'s (SHSE:688658) Last Week's 3.4% Decline Must Have Disappointed Private Companies Who Have a Significant Stake
Key Insights The considerable ownership by private companies in Youcare Pharmaceutical Group indicates that they collectively have a greater say in management and business strategy A total of 5 inve
Analysis
Price Target
No Data
